Cell-Free Glycoprotein Synthesis with Engineered E. coli Lysates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies struggle to precisely control protein glycosylation during glycoprotein synthesis, limiting the production of therapeutic glycoproteins.
Innovation Solution
A cell-free glycoprotein synthesis (CFGpS) system using engineered E. coli lysates that overexpress glycosyltransferases and oligosaccharyltransferases, enabling controllable glycosylation and producing up to 1-1.5 g/L protein, with a 50% yield increase compared to state-of-the-art systems.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional glycosylation systems are used, then glycoprotein synthesis can be performed, but manufacturing precision and control over glycosylation patterns are insufficient
Solution Approach 1:
The system segments the glycosylation process into distinct enzymatic steps by using separate glycosyltransferase enzymes, each responsible for adding specific sugar residues. This allows independent control and optimization of each glycosylation step, enabling precise control over glycan structure and composition.
Solution Approach 2:
The invention changes the biochemical parameters of the system by introducing engineered glycosyltransferases with modified catalytic properties. By altering enzyme specificity, substrate range, and reaction conditions, the system achieves precise control over glycosylation patterns while maintaining manufacturability.
2Productivity
If state-of-the-art glycosylation systems are used, then glycoproteins can be produced, but productivity and yield are limited
Solution Approach 1:
The system implements continuous glycosylation by using cell-free extracts that contain all necessary enzymes and substrates in a single reaction vessel. This eliminates the need for multiple sequential steps and allows continuous production of glycoproteins, significantly improving yield and reducing production time.
Solution Approach 2:
The invention performs preliminary preparation of cell-free extracts enriched with glycosylation components before the actual glycoprotein synthesis. This pre-processing step ensures that all necessary enzymes and substrates are ready in optimal concentrations, enabling rapid and efficient glycoprotein production without time-consuming in-situ enzyme preparation.
3Productivity
If engineered E. coli lysates with overexpressed glycosylation components are used, then glycoprotein yield increases by 50%, but device complexity increases
Solution Approach 1:
The system uses a universal cell-free expression system based on E. coli that can perform protein synthesis, RNA transcription, and glycosylation in a single platform. This multi-functional system eliminates the need for separate systems for each function, achieving high yield while managing overall system complexity through integration.
Solution Approach 2:
The invention introduces cell-free extracts as intermediary components that contain pre-assembled glycosylation machinery. These extracts serve as mediators between the genetic information and the final glycoprotein product, consolidating multiple functional components into a single usable reagent that simplifies the overall system while maintaining high productivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CFGpS system facilitates rapid, controllable glycosylation of therapeutic proteins, offering higher yields and improved production efficiency compared to existing methods.
Implementation Method 1
The disclosed non-naturally occurring strains of E. coli may be modified to overexpress glycosyltransferases and/or oligosaccharyltransferases
Data Source
AI summary
Disclosed are components and systems for cell-free glycoprotein synthesis (CFGpS). In particular, the components and systems include and utilize prokaryotic cell lysates from engineered prokaryotic cell strains that have been engineered to enable cell-free synthesis of glycoproteins.